Ukinuta odobrenja, povlačenje serija lijekova, pisma zdravstvenim radnicima i novi lijekovi EU — svakodnevno, automatski. Zadnje ažuriranje: 27. 9. 2026. 13:39
Izvori: promjene pratimo na temelju informacija Agencije za lijekove i medicinske proizvode (HALMED) — rješenja o ukidanju odobrenja, obavijesti o povlačenju serija i pisma zdravstvenim radnicima. Odluke o centralizirano odobrenim lijekovima dolaze iz registra Unije Europske komisije (oznaka EU). Nestašice i liste lijekova HZZO-a ovdje (još) nisu uključene.
br. EU/1/24/1800 · Squamous cell carcinoma of the anal canal (SCAC)
ZYNYZ is indicated in combination with carboplatin and pacli… · Incyte Biosciences Distribution B.V. · retifanlimab · ATC L01FF10
br. EU/1/24/1792 · Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxy… · Alexion Europe SAS · danicopan · ATC L04AJ09
br. EU/1/24/1801 · Plaque psoriasis
Pyzchiva is indicated for the treatment of moderate to severe plaque psoriasis in adults who… · Samsung Bioepis NL B.V. · ustekinumab · ATC L04AC05
br. EU/1/23/1788 · Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urin… · Vifor France · Sparsentan · ATC C09XX01
br. EU/1/24/1806 · Celldemic is indicated for active immunisation against H5N1 subtype of Influenza A virus in adults and infants… · Seqirus Netherlands B.V. · Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) · ATC J07BB02
Lekoskop